安旭生物
(688075)
| 流通市值：49.88亿 | | | 总市值：49.88亿 |
| 流通股本：1.27亿 | | | 总股本：1.27亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 229,747,240.9 | 115,296,526.87 | 540,698,462.1 | 403,268,418.25 |
| 营业收入 | 229,747,240.9 | 115,296,526.87 | 540,698,462.1 | 403,268,418.25 |
| 二、营业总成本 | 257,664,669.31 | 121,733,021.18 | 502,118,745.92 | 390,136,270.04 |
| 营业成本 | 139,893,380.26 | 66,503,782.6 | 329,275,112.29 | 233,453,244.12 |
| 税金及附加 | 10,320,644.81 | 2,017,173.67 | 6,713,216.98 | 3,961,441.87 |
| 销售费用 | 27,195,877.65 | 15,621,441.77 | 49,326,995.28 | 33,962,155.78 |
| 管理费用 | 22,987,458.38 | 10,391,007.73 | 54,101,092.92 | 35,038,148.2 |
| 研发费用 | 47,409,960.28 | 25,058,704.57 | 101,079,334.64 | 77,098,514.21 |
| 财务费用 | 9,857,347.94 | 2,140,910.84 | -38,377,006.19 | 6,622,765.86 |
| 其中:利息费用 | 1,004.27 | - | - | 31,169.43 |
| 其中:利息收入 | -1,112,596.77 | -392,745.68 | - | -3,265,415.53 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 22,444,815.69 | 11,317,050.23 | 63,426,961.5 | 25,393,515.39 |
| 加:投资收益 | 59,702,962.11 | 28,056,552.8 | 118,212,228.95 | 87,579,132.86 |
| 资产处置收益 | 131,398.95 | 159,342.19 | 4,610,768.06 | 4,512,279.88 |
| 资产减值损失(新) | - | - | -12,777,723.36 | -1,317,472.93 |
| 信用减值损失(新) | -1,673,669.58 | - | -12,550,014.6 | 124,743.78 |
| 其他收益 | 4,131,873.2 | 1,725,120.33 | 8,080,908.62 | 14,581,342.75 |
| 营业利润平衡项目 | 0 | 0.01 | 0 | 0 |
| 四、营业利润 | 56,819,951.96 | 34,821,571.25 | 207,582,845.35 | 144,005,689.94 |
| 加:营业外收入 | 4,707,679.88 | 54,346.4 | 3,525,594.15 | 130,751.08 |
| 减:营业外支出 | 36,770.76 | 35,969.92 | 468,351.54 | 129,878.12 |
| 五、利润总额 | 61,490,861.08 | 34,839,947.73 | 210,640,087.96 | 144,006,562.9 |
| 减:所得税费用 | 2,306,148.84 | 612,529.3 | 18,403,120.32 | 8,258,272.26 |
| 六、净利润 | 59,184,712.24 | 34,227,418.43 | 192,236,967.64 | 135,748,290.64 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 59,184,712.24 | 34,227,418.43 | - | 135,748,290.64 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 59,305,890.78 | 34,029,618.77 | 192,295,303.31 | 135,783,697.44 |
| 少数股东损益 | -121,178.54 | 197,799.66 | -58,335.67 | -35,406.8 |
| 扣除非经常损益后的净利润 | 23,586,168.33 | 22,760,297.27 | 37,897,947.37 | 19,378,861.71 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.47 | 0.27 | 1.51 | 1.07 |
| (二)稀释每股收益 | 0.47 | 0.27 | 1.51 | 1.07 |
| 八、其他综合收益 | -2,142,147.47 | -1,895,802.41 | 3,504,624.29 | 7,639,053.23 |
| 归属于母公司股东的其他综合收益 | -2,142,147.47 | -1,895,802.41 | 3,504,624.29 | 7,639,053.23 |
| 九、综合收益总额 | 57,042,564.77 | 32,331,616.02 | 195,741,591.93 | 143,387,343.88 |
| 归属于母公司股东的综合收益总额 | 57,163,743.31 | 32,133,816.36 | 195,799,927.6 | 143,422,750.68 |
| 归属于少数股东的综合收益总额 | -121,178.54 | 197,799.66 | -58,335.67 | -35,406.8 |
| 公告日期 | 2025-08-20 | 2025-04-30 | 2025-04-30 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |